HRP20201815T1 - Nukleinske kiseline za liječenje alergija - Google Patents
Nukleinske kiseline za liječenje alergija Download PDFInfo
- Publication number
- HRP20201815T1 HRP20201815T1 HRP20201815TT HRP20201815T HRP20201815T1 HR P20201815 T1 HRP20201815 T1 HR P20201815T1 HR P20201815T T HRP20201815T T HR P20201815TT HR P20201815 T HRP20201815 T HR P20201815T HR P20201815 T1 HRP20201815 T1 HR P20201815T1
- Authority
- HR
- Croatia
- Prior art keywords
- nucleic acid
- seq
- acid molecule
- treatment
- pharmaceutical composition
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims 28
- 108020004707 nucleic acids Proteins 0.000 title claims 22
- 102000039446 nucleic acids Human genes 0.000 title claims 22
- 206010020751 Hypersensitivity Diseases 0.000 title claims 8
- 230000007815 allergy Effects 0.000 title claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000013604 expression vector Substances 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 8
- 102000037865 fusion proteins Human genes 0.000 claims 8
- 208000026935 allergic disease Diseases 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims 5
- 239000013566 allergen Substances 0.000 claims 5
- 229940023146 nucleic acid vaccine Drugs 0.000 claims 5
- 206010016946 Food allergy Diseases 0.000 claims 3
- 208000008267 Peanut Hypersensitivity Diseases 0.000 claims 3
- 108010059830 limbic system-associated membrane protein Proteins 0.000 claims 3
- 201000010853 peanut allergy Diseases 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 claims 2
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 claims 2
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 206010048908 Seasonal allergy Diseases 0.000 claims 2
- 201000004338 pollen allergy Diseases 0.000 claims 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims 1
- 241001553178 Arachis glabrata Species 0.000 claims 1
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 1
- 235000018262 Arachis monticola Nutrition 0.000 claims 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000604993 Homo sapiens Lysosome-associated membrane glycoprotein 2 Proteins 0.000 claims 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 claims 1
- 108010076039 Polyproteins Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 102000057640 human CD63 Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020232 peanut Nutrition 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Claims (19)
1. Molekula nukleinske kiseline koja kodira himerni protein za upotrebu u liječenju alergije, pri čemu molekula nukleinske kiseline sadrži, spojene u okviru u redoslijedu koji slijedi jedan za drugim:
sekvencu nukleinske kiseline koja kodira signalnu sekvencu;
sekvencu nukleinske kiseline koja kodira luminalnu domenu ljudskog proteina membrane povezanog sa lizozomom (LAMP);
sekvencu nukleinske kiseline koja kodira protein alergena, pri čemu sekvenca nukleinske kiseline ne uključuje prirodnu signalnu sekvencu proteina alergena;
sekvencu nukleinske kiseline koja kodira transmembransku domenu ljudskog LAMP; i
sekvencu nukleinske kiseline koja kodira domenu za ciljanje ljudskog LAMP,
pri čemu je ljudski LAMP izabran od ljudskog LAMP-1, ljudskog LAMP-2, ljudskog CD63/LAMP-3, ili ljudskog DC LAMP.
2. Molekula nukleinske kiseline za upotrebu prema zahtjevu 1, pri čemu protein alergena sadrži najmanje jedan alergen koji je izabran od:
i) grupe koja se sastoji iz Cry J1 i Cry J2; ili
ii) poliproteina alergena kikirikija AraH1/AraH2/AraH3.
3. Molekula nukleinske kiseline za upotrebu prema zahtjevu 1, pri čemu:
i) himerni protein je himerni CRY J1-LAMP i pri čemu se himerni protein sastoji iz sekvence aminokiseline
koja je najmanje 90% identična sa SEQ ID NO: 5;
koja je najmanje 95% identična sa SEQ ID NO: 5;
koja je najmanje 98% identična sa SEQ ID NO: 5;
koja je najmanje 99% identična sa SEQ ID NO: 5; ili
koja se sastoji iz sekvence aminokiselina koja je predstavljena u SEQ ID NO: 5;
ii) himerni protein je himerni CRY J2-LAMP i pri čemu se himerni protein sastoji iz sekvence aminokiseline
koja je najmanje 90% identična sa SEQ ID NO: 3;
koja je najmanje 95% identična sa SEQ ID NO: 3;
koja je najmanje 98% identična sa SEQ ID NO: 3;
koja je najmanje 99% identična sa SEQ ID NO: 3; ili
koja se sastoji iz sekvence aminokiselina koja je predstavljena u SEQ ID NO: 3; ili
iii) himerni protein je himerni AraH-LAMP i pri čemu se himerni protein sastoji iz sekvence aminokiseline
koja je najmanje 90% identična sa SEQ ID NO: 9;
koja je najmanje 95% identična sa SEQ ID NO: 9;
koja je najmanje 98% identična sa SEQ ID NO: 9;
koja je najmanje 99% identična sa SEQ ID NO: 9; ili
koja se sastoji iz sekvence aminokiselina koja je predstavljena u SEQ ID NO: 9.
4. Molekula nukleinske kiseline za upotrebu prema bilo kojem od zahtjeva 1-3, pri čemu se molekula nukleinske kiseline sastoji iz DNK.
5. Ekspresijski vektor koji se sastoji iz molekula nukleinske kiseline prema bilo kojem od zahtjeva 1-4 za upotrebu u liječenju alergije.
6. Farmaceutski sastav koja se sastoji iz ekspresijskog vektora koji sadrži molekulu nukleinske kiseline prema bilo kojem od zahtjeva 1-4 za upotrebu u liječenju alergije, koji po potrebi sadrži farmaceutski prihvatljiv nosač.
7. Farmaceutski sastav prema zahtjevu 6 za upotrebu u liječenju alergije.
8. Cjepivo nukleinske kiseline koje sadrži farmaceutski sastav prema zahtjevu 6 ili 7 za upotrebu u liječenju alergije.
9. Farmaceutski sastav koji se sastoji iz ekspresijskog vektora koji sadrži molekulu nukleinske kiseline prema zahtjevu 2i), zahtjevu 3i) ili zahtjevu 3ii) za upotrebu u liječenju alergije na pelud, pri čemu se molekula nukleinske kiseline sastoji iz DNK, i po potrebi gdje farmaceutski sastav sadrži farmaceutski prihvatljiv nosač.
10. Cjepivo nukleinske kiseline koje se sastoji iz farmaceutskog sastava koje sadrži ekspresijski vektor koji se sastoji iz molekula nukleinske kiseline prema zahtjevu 2i), zahtjevu 3i) ili zahtjevu 3ii) za upotrebu u liječenju alergije, pri čemu se molekula nukleinske kiseline sastoji iz DNK, i po potrebi gdje farmaceutski sastav sadrži farmaceutski prihvatljiv nosač.
11. Cjepivo nukleinske kiseline prema zahtjevu 10 za upotrebu u liječenju alergije na pelud.
12. Farmaceutski sastav koji se sastoji iz ekspresijskog vektora koji sadrži molekulu nukleinske kiseline prema zahtjevu 2ii) ili zahtjevu 3iii) za upotrebu u liječenju alergije na kikiriki, pri čemu se molekula nukleinske kiseline sastoji iz DNK, i po potrebi gdje farmaceutski sastav sadrži farmaceutski prihvatljiv nosač.
13. Cjepivo nukleinske kiseline koje se sastoji iz farmaceutskog sastava koji sadrži ekspresijski vektor koji sadrži molekulu nukleinske kiseline prema zahtjevu 2ii) ili zahtjevu 3iii) za upotrebu u liječenju alergije, pri čemu se molekula nukleinske kiseline sastoji iz DNK, i po potrebi gdje farmaceutski sastav sadrži farmaceutski prihvatljiv nosač.
14. Cjepivo nukleinske kiseline prema zahtjevu 13 za upotrebu u liječenju alergije na kikiriki.
15. Molekula nukleinske kiseline koja kodira himerni protein koji se sastoji iz aminokiseline koja je predstavljena u SEQ ID NO: 9.
16. Molekula nukleinske kiseline prema zahtjevu 15, pri čemu se molekula nukleinske kiseline sastoji iz DNK.
17. Ekspresijski vektor koji se sastoji iz molekula nukleinske kiseline prema zahtjevu 16.
18. Farmaceutski sastav koja sadrži ekspresijski vektor koji se sastoji iz molekula nukleinske kiseline prema zahtjevu 16 i farmaceutski prihvatljivog nosača.
19. Farmaceutski sastav prema zahtjevu 18 za upotrebu u liječenju alergije na kikiriki.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12878776.9A EP2861240B1 (en) | 2012-06-15 | 2012-06-15 | Nucleic acids for treatment of allergies |
| PCT/US2012/042552 WO2013187906A1 (en) | 2012-06-15 | 2012-06-15 | Nucleic acids for treatment of allergies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201815T1 true HRP20201815T1 (hr) | 2021-02-19 |
Family
ID=49758576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201815TT HRP20201815T1 (hr) | 2012-06-15 | 2020-11-16 | Nukleinske kiseline za liječenje alergija |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9744230B2 (hr) |
| EP (2) | EP3808361A1 (hr) |
| JP (1) | JP5807994B2 (hr) |
| KR (2) | KR102386481B1 (hr) |
| CN (2) | CN104519896B (hr) |
| AU (3) | AU2012382406B2 (hr) |
| BR (1) | BR112014031327B1 (hr) |
| CA (1) | CA2876824C (hr) |
| CY (1) | CY1123769T1 (hr) |
| DK (1) | DK2861240T3 (hr) |
| ES (1) | ES2831723T3 (hr) |
| HR (1) | HRP20201815T1 (hr) |
| HU (1) | HUE052481T2 (hr) |
| IL (4) | IL236174B (hr) |
| LT (1) | LT2861240T (hr) |
| PL (1) | PL2861240T3 (hr) |
| PT (1) | PT2861240T (hr) |
| RS (1) | RS61098B1 (hr) |
| SI (1) | SI2861240T1 (hr) |
| WO (1) | WO2013187906A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160185831A1 (en) * | 2011-06-14 | 2016-06-30 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
| PL2861240T3 (pl) | 2012-06-15 | 2021-07-05 | Immunomic Therapeutics, Inc. | Kwasy nukleinowe do leczenia alergii |
| EP3964232A1 (en) | 2012-10-30 | 2022-03-09 | Aravax Pty Ltd | Novel immunotherapeutic molecules and uses thereof |
| BR112016006813A2 (pt) | 2013-09-25 | 2017-09-19 | Aravax Pty Ltd | Composição imunoterapêutica nova e seus usos |
| EP3157558A2 (en) * | 2014-06-23 | 2017-04-26 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of peanut allergies |
| US10143742B2 (en) | 2015-02-20 | 2018-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US11452774B2 (en) | 2015-02-20 | 2022-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10166286B2 (en) | 2015-02-20 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10149904B2 (en) | 2015-02-20 | 2018-12-11 | The Board Of Trusteees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| MX2018007841A (es) | 2015-12-23 | 2018-11-09 | Medigene Immunotherapies Gmbh | Composicion de celula dendritica. |
| CA3044074A1 (en) * | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
| BR112019022108A2 (pt) * | 2017-04-22 | 2020-05-12 | Immunomic Therapeutics, Inc. | Construções de lamp aprimoradas |
| WO2018204534A1 (en) * | 2017-05-02 | 2018-11-08 | Immunomic Therapeutics, Inc. | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens |
| SG11202000419QA (en) | 2017-07-18 | 2020-02-27 | Before Brands Inc | Methods for making mixed allergen compositions |
| EP3779443A4 (en) * | 2018-04-06 | 2022-05-04 | Slsbio Co., Ltd. | NEW IMMUNOGLOBULIN E EPITOPE, BINDING ANTIBODY AND KIT FOR THE ANALYSIS OF IMMUNOGLOBULIN E IN A SAMPLE CONTAINING IT |
| US20210163549A1 (en) | 2018-05-11 | 2021-06-03 | Astellas Pharma Inc. | Nucleic acid for treating crustacean allergy |
| AR115379A1 (es) | 2018-05-11 | 2021-01-13 | Astellas Pharma Inc | Ácido nucleico para tratar alergia a los ácaros |
| EP3793595A1 (en) * | 2018-05-15 | 2021-03-24 | Immunomic Therapeutics, Inc. | Improved lamp constructs comprising allergens |
| EP3914098A1 (en) | 2019-01-23 | 2021-12-01 | Before Brands, Inc. | Methods for making mixed allergen compositions |
| EP3938053A4 (en) * | 2019-03-13 | 2023-03-22 | Psomagen, Inc. | EPITOPE-BASED APPROACH TO ALLERGY TREATMENTS AND CROHN'S DISEASE INHIBITORS |
| AU2022321271A1 (en) * | 2021-08-06 | 2024-02-29 | Kao Corporation | Nucleic acid structure utilizing snare |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD335810S (en) | 1990-07-02 | 1993-05-25 | Dick-Ming Asien | Handle for luggage or similar article |
| US6090386A (en) | 1991-07-12 | 2000-07-18 | Griffith; Irwin J. | T cell peptides of the CRX JII allergen |
| US6982326B1 (en) | 1991-07-12 | 2006-01-03 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from Japanese cedar pollen |
| WO1994024281A1 (en) * | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| JPH08505284A (ja) * | 1992-11-12 | 1996-06-11 | イミュロジック ファーマスーティカル コーポレイション | 杉花粉由来のアレルゲン性蛋白質及びペプチド |
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| JP3649460B2 (ja) | 1993-11-05 | 2005-05-18 | 明治乳業株式会社 | スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ |
| GB9516760D0 (en) | 1995-08-16 | 1995-10-18 | Sandoz Ltd | Organic compounds |
| CA2241918C (en) | 1995-12-29 | 2008-12-02 | University Of Arkansas | Peanut allergens and methods |
| US7112329B1 (en) | 1996-06-14 | 2006-09-26 | Meiji Milk Products Co. Ltd. | T cell epitope peptide |
| AU2001251407A1 (en) * | 2000-04-07 | 2001-10-23 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
| WO2002074250A2 (en) | 2001-03-16 | 2002-09-26 | Panacea Pharmaceuticals | Methods and reagents for decreasing clinical reaction to allergy |
| US8318173B2 (en) | 2001-04-05 | 2012-11-27 | The John Hopkins University | Chimeric vaccines |
| US20060003148A1 (en) | 2004-06-30 | 2006-01-05 | Zwynenburg James L | Interlocking polymeric foam floor underlayment and process for making |
| WO2006099574A2 (en) * | 2005-03-16 | 2006-09-21 | Tai June Yoo | Cockroach allergen gene expression and delivery systems and uses |
| US20090304738A1 (en) | 2005-06-16 | 2009-12-10 | Moran Thomas M | Methods for Enhancing Immune Responses |
| US7566456B2 (en) | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| EP1932538A4 (en) * | 2005-08-25 | 2009-10-21 | Taiho Pharmaceutical Co Ltd | BIODEGRADABLE NANOTEHICLES WITH IMMOBILIZED OR CAPACITATED T-CELL-RECOGNIZABLE EPITOPEPEPID |
| US20080006554A1 (en) | 2006-07-07 | 2008-01-10 | Medtronic Vascular, Inc. | Packaging assembly for a catheter |
| EP2042193A1 (en) * | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
| WO2010029317A2 (en) * | 2008-09-10 | 2010-03-18 | Ibd Column Therapies International Ab | Treating inflammatory conditions |
| PL2861240T3 (pl) | 2012-06-15 | 2021-07-05 | Immunomic Therapeutics, Inc. | Kwasy nukleinowe do leczenia alergii |
-
2012
- 2012-06-15 PL PL12878776T patent/PL2861240T3/pl unknown
- 2012-06-15 CN CN201280075163.5A patent/CN104519896B/zh active Active
- 2012-06-15 DK DK12878776.9T patent/DK2861240T3/da active
- 2012-06-15 PT PT128787769T patent/PT2861240T/pt unknown
- 2012-06-15 AU AU2012382406A patent/AU2012382406B2/en active Active
- 2012-06-15 EP EP20194785.0A patent/EP3808361A1/en not_active Withdrawn
- 2012-06-15 CA CA2876824A patent/CA2876824C/en active Active
- 2012-06-15 ES ES12878776T patent/ES2831723T3/es active Active
- 2012-06-15 SI SI201231855T patent/SI2861240T1/sl unknown
- 2012-06-15 JP JP2015517226A patent/JP5807994B2/ja active Active
- 2012-06-15 LT LTEP12878776.9T patent/LT2861240T/lt unknown
- 2012-06-15 KR KR1020207012427A patent/KR102386481B1/ko active IP Right Grant
- 2012-06-15 KR KR1020157000696A patent/KR102107646B1/ko active IP Right Grant
- 2012-06-15 WO PCT/US2012/042552 patent/WO2013187906A1/en unknown
- 2012-06-15 CN CN201710999629.5A patent/CN107937423A/zh active Pending
- 2012-06-15 BR BR112014031327-0A patent/BR112014031327B1/pt active IP Right Grant
- 2012-06-15 HU HUE12878776A patent/HUE052481T2/hu unknown
- 2012-06-15 RS RS20201379A patent/RS61098B1/sr unknown
- 2012-06-15 EP EP12878776.9A patent/EP2861240B1/en active Active
-
2014
- 2014-12-11 IL IL23617414A patent/IL236174B/en active IP Right Grant
-
2016
- 2016-03-02 US US15/058,224 patent/US9744230B2/en active Active
-
2017
- 2017-07-31 US US15/663,871 patent/US10072053B2/en active Active
-
2018
- 2018-01-25 AU AU2018200625A patent/AU2018200625B2/en active Active
-
2019
- 2019-10-18 AU AU2019250227A patent/AU2019250227B2/en active Active
- 2019-10-29 IL IL270260A patent/IL270260B/en active IP Right Grant
- 2019-10-29 IL IL270261A patent/IL270261B/en active IP Right Grant
- 2019-10-29 IL IL270262A patent/IL270262A/en unknown
-
2020
- 2020-09-22 US US17/028,762 patent/US20220081474A1/en active Pending
- 2020-11-16 HR HRP20201815TT patent/HRP20201815T1/hr unknown
- 2020-11-23 CY CY20201101107T patent/CY1123769T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201815T1 (hr) | Nukleinske kiseline za liječenje alergija | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| BR112013032723A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| BR112013029409A8 (pt) | produtos farmacêuticos de peptídeo melhorados para resistência à insulina | |
| BRPI0922867B8 (pt) | glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada | |
| EA201170635A1 (ru) | Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii | |
| MX356517B (es) | Polipéptidos de fusión de serpina y métodos de uso de los mismos. | |
| BR112013020338A2 (pt) | proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira | |
| CO6690759A2 (es) | Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb | |
| WO2010150233A3 (en) | Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof | |
| GT200500254A (es) | Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados. | |
| BRPI0815578B8 (pt) | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina | |
| AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| UA107571C2 (xx) | Фармацевтична композиція | |
| DK2027152T3 (da) | Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner | |
| ECSP088262A (es) | Proteínas de fusión de albúmina | |
| MX358762B (es) | Procesos que utilizan vlps con cápsides resistentes a hidrolasas. | |
| DK2010563T3 (da) | Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi | |
| US20240150409A1 (en) | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses | |
| BR112015003947A8 (pt) | Proteínas de fusão e métodos para tratar, prevenir ou melhorar dor | |
| CO6210831A2 (es) | Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina |